UCB Full Year 2016 Results Earnings Presentation

UCB presented its full-year 2016 financial results on February 23, 2017, outlining its patient-focused innovation strategy and sustainable growth across its biopharmaceutical portfolio. The presentation highlights UCB's commitment to delivering differentiated solutions in therapeutic areas including epilepsy and rheumatoid arthritis through a networked, cross-functional approach.